Vanda Pharmaceuticals Inc
VNDA4.260USD
+0.070+1.67%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
251.68MValor de mercado
PerdaP/L TTM
Mais detalhes de Vanda Pharmaceuticals Inc Empresa
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Informações da empresa
Código da empresaVNDA
Nome da EmpresaVanda Pharmaceuticals Inc
Data de listagemApr 12, 2006
CEODr. Mihael Hristos Polymeropoulos, M.D.
Número de funcionários368
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 12
EndereçoSuite 300E
CidadeWASHINGTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal20037
Telefone12027343400
Sitehttps://www.vandapharma.com/
Código da empresaVNDA
Data de listagemApr 12, 2006
CEODr. Mihael Hristos Polymeropoulos, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.33M
+1.31%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
97.08K
+116.43%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.33M
+1.31%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Fanapt
23.55M
47.05%
Hetlioz
20.87M
41.71%
PONVORY
5.62M
11.24%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Fanapt
23.55M
47.05%
Hetlioz
20.87M
41.71%
PONVORY
5.62M
11.24%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.18%
Renaissance Technologies LLC
6.04%
The Vanguard Group, Inc.
5.92%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.30%
Other
68.29%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.18%
Renaissance Technologies LLC
6.04%
The Vanguard Group, Inc.
5.92%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.30%
Other
68.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor
28.86%
Investment Advisor/Hedge Fund
26.88%
Hedge Fund
19.28%
Individual Investor
7.20%
Research Firm
2.93%
Pension Fund
0.44%
Bank and Trust
0.20%
Sovereign Wealth Fund
0.20%
Venture Capital
0.12%
Other
13.90%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
415
50.78M
86.17%
-11.31M
2025Q1
426
48.51M
82.37%
-12.27M
2024Q4
444
46.48M
79.71%
-15.23M
2024Q3
446
47.42M
81.36%
-14.93M
2024Q2
445
46.99M
80.73%
-18.42M
2024Q1
434
53.50M
92.97%
-11.41M
2023Q4
445
55.38M
96.27%
-9.21M
2023Q3
446
56.79M
98.75%
-12.15M
2023Q2
434
60.42M
105.19%
-10.16M
2023Q1
437
62.04M
109.27%
-2.85M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
6.02M
10.21%
+16.86K
+0.28%
Mar 31, 2025
Renaissance Technologies LLC
3.57M
6.05%
-287.37K
-7.46%
Mar 31, 2025
The Vanguard Group, Inc.
3.50M
5.93%
-11.00K
-0.31%
Mar 31, 2025
Millennium Management LLC
3.12M
5.29%
+980.75K
+45.84%
Jun 27, 2025
Dimensional Fund Advisors, L.P.
2.54M
4.31%
+51.16K
+2.06%
Mar 31, 2025
Tang Capital Management, LLC
2.35M
3.99%
--
--
Mar 31, 2025
Polymeropoulos (Mihael Hristos)
2.33M
3.95%
+30.00K
+1.31%
May 21, 2025
BlackRock Financial Management, Inc.
2.15M
3.64%
+14.97K
+0.70%
Mar 31, 2025
Acadian Asset Management LLC
1.89M
3.2%
-12.95K
-0.68%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.61M
2.74%
+163.33K
+11.26%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Neuroscience and Healthcare ETF
0.64%
Invesco NASDAQ Future Gen 200 ETF
0.49%
ALPS Medical Breakthroughs ETF
0.19%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.13%
Fidelity Small-Mid Multifactor ETF
0.09%
Federated Hermes MDT Small Cap Core ETF
0.08%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Franklin US Small Cap Multifactor Index ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.03%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção0.64%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.49%
ALPS Medical Breakthroughs ETF
Proporção0.19%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proporção0.13%
Fidelity Small-Mid Multifactor ETF
Proporção0.09%
Federated Hermes MDT Small Cap Core ETF
Proporção0.08%
iShares Micro-Cap ETF
Proporção0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.04%
Franklin US Small Cap Multifactor Index ETF
Proporção0.04%
Fidelity Enhanced Small Cap ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
